CoSyne Therapeutics

CoSyne Therapeutics is a London-based AI drug discovery company focused on glioblastoma multiforme — the most aggressive and treatment-resistant primary brain cancer, for which median survival following diagnosis remains under 18 months. The company was founded on the conviction that the key to unlocking better treatments lies not in developing new molecules in isolation, but in understanding the molecular heterogeneity within tumours well enough to identify which patients will respond to which therapies — and then developing drugs that precisely target those vulnerabilities.

CoSyne uses a polymathic AI platform that combines computational systems biology, multi-omic genomic analysis, and machine learning to model the complex interactions between cancer cell populations and therapeutic interventions. This approach enables the company to stratify patients based on their tumour's molecular profile, identify existing drugs that may be repurposed for specific patient subgroups, and design novel small molecule candidates for the most treatment-resistant disease states. The team brings together experts in mathematics, biology, chemistry, physics, healthcare, and AI from institutions including Cambridge's Milner Therapeutics Institute.

CoSyne Therapeutics has raised £3.3 million from investors including BACKED VC, Amino Collective, and Phoenix Court. The company is headquartered in London's Soho with laboratory operations in Cambridge, and has published pre-print research demonstrating meaningful advances in molecular drug response stratification for brain tumours. Its work has attracted attention from the global glioblastoma research community as one of the most technically ambitious approaches to precision medicine in neuro-oncology.